These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 18577154)

  • 21. The relationship between self-monitored blood glucose values and glycated haemoglobin in insulin-treated patients with Type 2 diabetes.
    Sarwat S; Ilag LL; Carey MA; Shrom DS; Heine RJ
    Diabet Med; 2010 May; 27(5):589-92. PubMed ID: 20536957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.
    Owens DR; Luzio SD; Sert-Langeron C; Riddle MC
    Diabetes Obes Metab; 2011 Nov; 13(11):1020-7. PubMed ID: 21679291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin glargine and its role in glycaemic management of Type 2 diabetes.
    Elrishi MA; Jarvis J; Khunti K; Davies MJ
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1099-110. PubMed ID: 18680444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus.
    Raccah D
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():76-82. PubMed ID: 18577159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients.
    Schreiber SA; Haak T
    Diabetes Obes Metab; 2007 Jan; 9(1):31-8. PubMed ID: 17199716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.
    Rosenstock J; Lorber DL; Gnudi L; Howard CP; Bilheimer DW; Chang PC; Petrucci RE; Boss AH; Richardson PC
    Lancet; 2010 Jun; 375(9733):2244-53. PubMed ID: 20609970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.
    Zinman B; Fulcher G; Rao PV; Thomas N; Endahl LA; Johansen T; Lindh R; Lewin A; Rosenstock J; Pinget M; Mathieu C
    Lancet; 2011 Mar; 377(9769):924-31. PubMed ID: 21396703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine.
    Rosenstock J; Eliaschewitz FG; Heilmann CR; Muchmore DB; Hayes RP; Belin RM
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S63-73. PubMed ID: 19772451
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents.
    Wolffenbuttel BH; Klaff LJ; Bhushan R; Fahrbach JL; Jiang H; Martin S
    Diabet Med; 2009 Nov; 26(11):1147-55. PubMed ID: 19929994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term efficacy of insulin glargine plus oral antidiabetic agents in a 32-month observational study of everyday clinical practice.
    Schreiber SA; Ferlinz K; Haak T
    Diabetes Technol Ther; 2008 Apr; 10(2):121-7. PubMed ID: 18260775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus.
    McKeage K; Goa KL
    Drugs; 2001; 61(11):1599-624. PubMed ID: 11577797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.